Thermo Fisher Scientific has secured rights to distribute Biocartis Group’s Idylla automated molecular diagnostics testing platform and its accompanying assays in the US.
The Idylla platform is a fully integrated system that will allow laboratories to be used in a range of applications in oncology and beyond.
As per terms of the deal, Thermo Fisher Scientific will secure distribution rights for Biocartis’ Idylla molecular diagnostic assays for its customers in the US.
Biocartis will hold the right to sell both its Idylla platform and assays through direct sales channels.
Launched first in September 2014, the Idylla platform allows Thermo Fisher Scientific to provide fully automated and real-time PCR-based molecular diagnostics system for its US customers.
The molecular diagnostics system is said to offer fast and easy access to molecular biomarker information.
Idylla platform covers the entire process from sample to result in a time frame of about five hours.
Within two minutes, Idylla can be applied to a range of clinical sample types. It helps to analyze both RNA and DNA directly from formalin-fixed paraffin embedded sample.
The partnership plans to make the platform commercially available to the customers from mid-2017.
Biocartis CEO Rudi Pauwels said: “Thermo Fisher Scientific is a great match for Biocartis, holding an impressive track-record in improving patient diagnostics and increasing laboratory productivity.”
Thermo Fisher healthcare market channel general manager and vice president Mark Zacur said: “The Biocartis molecular diagnostics platform and assays are an important step forward in the fight against cancer.”